0001062993-22-019587.txt : 20220915
0001062993-22-019587.hdr.sgml : 20220915
20220915185443
ACCESSION NUMBER: 0001062993-22-019587
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220913
FILED AS OF DATE: 20220915
DATE AS OF CHANGE: 20220915
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GILLIS STEVEN
CENTRAL INDEX KEY: 0001229592
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39615
FILM NUMBER: 221246708
MAIL ADDRESS:
STREET 1: 8755 W. HIGGINS ROAD
STREET 2: SUITE 1025
CITY: CHICAGO
STATE: IL
ZIP: 60631
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Codiak BioSciences, Inc.
CENTRAL INDEX KEY: 0001659352
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 35 CAMBRIDGEPARK DRIVE
STREET 2: SUITE 500
CITY: CAMBRIDGE
STATE: MA
ZIP: 02140
BUSINESS PHONE: 617-949-4100
MAIL ADDRESS:
STREET 1: 35 CAMBRIDGEPARK DRIVE
STREET 2: SUITE 500
CITY: CAMBRIDGE
STATE: MA
ZIP: 02140
FORMER COMPANY:
FORMER CONFORMED NAME: Codiak Biosciences, Inc.
DATE OF NAME CHANGE: 20151125
4
1
form4.xml
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
X0306
4
2022-09-13
0001659352
Codiak BioSciences, Inc.
CDAK
0001229592
GILLIS STEVEN
C/O ARCH VENTURE PARTNERS
8755 WEST HIGGINS ROAD, SUITE 1025
CHICAGO
IL
60631
1
0
0
0
Common Stock
2022-09-13
4
P
0
5000000
A
7503903
I
See footnotes
Common Stock
10250
D
Warrant (Right to Buy)
1.875
2022-09-13
4
P
0
5000000
A
2022-09-13
2027-09-13
Common Stock
5000000
5000000
I
See footnotes
Shares purchased in a private investment in public equity transaction on September 13, 2022. Accompanying the Common Stock is one Series A Warrant to purchase one share of common stock at an exercise price of $1.875 per share.
Shares and warrants held by ARCH Venture Fund VIII, L.P. ("ARCH Fund VIII"). The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P. ("ARCH Partners VIII"), which may be deemed to beneficially own the shares and warrants held by ARCH Fund VIII. The sole general partner of ARCH Partners VIII is ARCH Venture Partners VIII, LLC ("ARCH VIII LLC"), which may be deemed to beneficially own the shares and warrants held by ARCH Fund VIII. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such shares and warrants, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares and warrants held by ARCH Fund VIII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares and warrants, except to the extent of any pecuniary interest therein.
The Reporting Person is a managing director at ARCH Partners VIII and owns an interest in ARCH Partners VIII but does not have voting or investment control over the shares and warrants held by ARCH Fund VIII. The Reporting Person disclaims beneficial ownership of such shares and warrants, except to the extent of any pecuniary interest therein.
/s/ Mark McDonnell by Power of Attorney for Steven Gillis
2022-09-15